EDP-322

DRUG2 trials

Sponsors

Enanta Pharmaceuticals, Inc

Conditions

MRSA, SSTIMethicillin-resistant Staphylococcus AureusSkin and Soft Tissue Infections

Phase 1

Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

CompletedNCT00990145

Enanta Pharmaceuticals, IncMRSA, SSTI

Start: 2008-11-30End: 2009-09-30Updated: 2009-10-08

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

CompletedNCT00989872

Enanta Pharmaceuticals, IncMethicillin-resistant Staphylococcus Aureus, Skin and Soft Tissue Infections

Updated: 2009-10-06